Palisade Bio (PALI) Projected to Post Quarterly Earnings on Tuesday

Palisade Bio (NASDAQ:PALI) is expected to release its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Palisade Bio to post earnings of ($0.32) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 7:00 AM ET.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). On average, analysts expect Palisade Bio to post $-12 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Palisade Bio Trading Down 3.9%

PALI stock traded down $0.08 during trading on Tuesday, hitting $1.92. The company had a trading volume of 218,071 shares, compared to its average volume of 2,930,093. The company has a fifty day moving average price of $1.22 and a two-hundred day moving average price of $0.93. The company has a market cap of $17.53 million, a P/E ratio of -0.47 and a beta of 1.59. Palisade Bio has a fifty-two week low of $0.53 and a fifty-two week high of $3.30.

Analyst Ratings Changes

A number of research firms have recently weighed in on PALI. Wall Street Zen upgraded Palisade Bio to a “sell” rating in a research report on Saturday, September 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Palisade Bio has a consensus rating of “Hold” and an average target price of $12.00.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.